Compare BioNTech SE - ADR (BNTX) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Norfolk Southern Corporation — how do they compare? BioNTech SE - ADR trades at $92.9 (market cap $23.31B), while Norfolk Southern Corporation trades at $333.32 (market cap $75.15B). The key difference: Norfolk Southern Corporation is far larger — about 3.2× BioNTech SE - ADR's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | NSC | |
|---|---|---|
Market Cap | $23.31B | $75.15B |
Sector | Health | Technology |
52-Week High | $119.34 | $350.66 |
52-Week Low | $83.89 | $272.35 |
Enterprise Value | $6.60B | $90.70B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Norfolk Southern (NSC) trades at $332.82, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $3.52 per share, beating estimates, driven by record revenue and volume growth. Valuation ratios like P/E of 28.55 and P/S of 5.99 indicate a premium, while profitability remains solid with a net income margin of 21.02% and ROE of 16.97%. Recent news highlights merger developments with Union Pacific and institutional interest.
Outlook is cautiously optimistic due to earnings momentum and industry tailwinds, but risks include high fuel costs, merger execution uncertainties, and premium valuation. Analysts give a mixed consensus with 43.75% buy ratings and a $369.67 price target, suggesting modest upside potential from current levels amid competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
